Targeted Cancer Therapies Bring New Precision Medicine Tools to Anatomic Pathologists and Clinical Laboratories

FDA is streamlining how new diagnostic tests are approved; encourages IVD companies to focus on ‘qualifying biomarkers’ in development of new cancer drugs It is good news for the anatomic pathology profession that new insights into the human immune system are triggering not only a wave of new therapeutic drugs, but also the need for companion diagnostic tests that help physicians decide when it is appropriate to prescribe immunotherapy drugs. Rapid advances in precision medicine, and the...

Pathologists and Research Team at Dana-Farber/Brigham and Women’s Use Next-Gen Sequencing to Create Faster, More Accurate Cancer Test

This advanced medical laboratory test looks for 95 genetic mutations associated with cancers of the blood and may provide pathologists with a new diagnostic tool  Seeking a faster time to answer when diagnosing patients with cancers of the blood, researchers and pathologists at the Dana-Farber/Brigham and Women’s Cancer Center (DF/BWCC) in Boston have developed a unique clinical laboratory assay that involves multiple genes and just takes days to perform. This high-tech genetic diagnostic test...

Experts Predict Explosive Growth in Molecular Diagnostics and Next-Generation Gene Sequencing for Clinical Pathology Laboratories

Upcoming Executive War College conference features experts on molecular and genetic testing Explosive rates of growth in clinical use of molecular diagnostics assays seen in recent years are about to be matched by a new opportunity for medical laboratory testing. Experts predict the coming “big thing” in clinical laboratory and anatomic pathology will be next-generation gene sequencing (NGS). This should be welcome news for financially-beleaguered pathology groups and clinical lab...
;